With limited clinical trials on stem cell therapy for adult stroke underway, the assessment of efficacy also needs to be considered for neonatal hypoxic-ischemic brain injury, considering its distinct symptoms. The critical nature of this condition leads to establishment of deficits that last a lifetime. Here, we will highlight the progress of current translational research, commenting on the critical nature of the disease, stem cell sources, the use of hypothermia, safety and efficacy of each treatment, modes of action, and the possibility of combination therapy. With this in mind, we reference translational guidelines established by a consortium of research partners called Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS). The guidelines of STEPS are directed toward evaluating outcomes of cell therapy in adult stroke; however, we identify the overlapping pathology, as we believe that these guidelines will serve well in the investigation of neonatal hypoxic-ischemic therapy.
Given that cerebral palsy (CP) is the most common motor disorder in children, with an estimated incidence of 1.5 to more than 4 per 1000 live births worldwide [1] , urgent research into translational therapy is essential in preventing the long-term cognitive and motor disabilities. These deficits are subsequent to conditions that may alter normal development of a child's brain or directly damage the developing brain of a child. Historically, the etiology of the disease was heavily regarded as an interruption in oxygen delivery, producing a hypoxicischemic environment that leads to deprivation of crucial oxygen, stunting neurological development. More recently, however, this paradigm began shifting to encompass more diverse risk factors that may lead to CP. These factors are further divided into congenital and acquired.
Several currently considered risk factors for congenital CP subscribe to a gestational or peripartum event inciting injury to the developing brain. Some of these factors include premature birth, low birth weight, multiple births, assisted reproduction, infections, jaundice, kernicterus, birth complications, and additional medical conditions of the mother. Many of these conditions may include fetal hypoxia, such as eclampsia, umbilical cord disruption, and even uterine rupture.
In contrast to many of the risk factors for congenital CP, acquired CP follows events occurring further postpartum. These causes seem to follow a more direct incident, yet still include risk factors producing hypoxia. Brain infections (Meningococcal meningitis), direct traumatic brain injury, and cerebral vascular disease may all predispose the developing brain to CP.
In addition to CP, hypoxic-ischemic encephalopathy (HIE), neonatal encephalopathy, and periventricular leukomalacia all share a common denominator of neonatal hypoxicischemic brain injury. Often, children with hypoxic-ischemic brain injuries will present with neurodevelopmental deficits such as hearing and visual impairments, learning disabilities, and mental retardation. More specifically, early signs of CP include failure to reach motor or movement milestones and a stiff, floppy appearance in younger children. However, because of many of these signs being nonspecific, early developmental monitoring and screening is critical in obtaining a diagnosis. Additional observations in HIE include seizure onset beyond the first 12 h of life, also associated with severe brain injury [2] , further encouraging prompt treatment.
Beyond just the morbidity, the mortality rates in HIE are staggering. Mortality rates are as high as 50% in HIE [3] , with 25% of survivors having CP [4] . Further, 30% of CP has been attributed to ischemic perinatal stroke [5] .
The remainder of this review will outline the development of promising translational therapy options that seek to reduce the sequelae of CP (hereafter also referred to as HIE or neonatal hypoxic-ischemic injury), starting with cell-based therapies and then describing hypothermic treatments. We will conclude this review with a discussion of prospective future therapies, detailing a current case report involving the first autologous cell therapy for CP in a young boy with hypoxic-ischemic brain injury following cardiac arrest.
Cell therapy as a treatment for neonatal hypoxic-ischemic injury
Because of the homology that exists between the pathophysiology of neonatal hypoxic-ischemic brain injury and adult stroke, currently evolving cell-based therapies for stroke may prove to be effective in the younger populations. One such target for intervention includes exploration of the NMDA receptor function. Increased excitation coupled with aberrant oxidative stress, secondary to mitochondrial dysfunction, leads to the depletion of cellular energy of neurons in the brain of babies with HIE [6] , a condition referred to as 'secondary energy failure' or 'excitotoxic-oxidative cascade' [6] . Presently, the treatment protocol for HIE involves a reduction in the metabolic demand, complementing the reduction in available energy, through the induction of hypothermia [7, 8] . This treatment is most effective in newborns with a gestational age greater than or equal to 36 weeks [8] ; however, nearly half of all treated patients still have persistent deficits after therapy [8] .
Transplantable stem cell characteristics
In considering stem cell transplantation as a therapeutic option for HIE, the diverse characteristics of stem cells introduce a variety of treatment approaches. First, we must classify a well-defined phenotype to better understand the biology, mechanism of action, and safety and efficacy of a cell population [9] . Next, we need to consider how the theory of cell-based transplant therapy is evolving with emerging research. Originally, the concept of cell transplant in brain injury was thought to be a mechanism of neuronal cell replacement. This prospective is progressing to a more multifaceted restorative mechanism, in which transplanted cells may not only directly replace damaged cells but facilitate an environment conducive to endogenous repair through trophic, neurogenic, vasculogenic, angiogenic, and synaptogenic properties [10] . Cellular replacement and the aforementioned bystander effects constitute the two major modes of action implicated in stem cell-mediated functional recovery in ischemic brain injury [11] . Finally, we must consider the factors contributing to the development of a clinical product for treatment in a clinical setting, factors such as transplantation method and stem cell derivation. The ideal would be the development of an injectable, autologous transplantation technique. Potential sites for autologous harvesting include craniofacial neural crest cells or fibroblasts for generating induced pluripotent stem cells. The use of autologous cells would circumvent the potential for graft rejection. Prior preliminary studies have demonstrated safety in intravenous injection of autologous cord blood in children [12] . Additional potential sources for stem cells have been reviewed previously by our team [13] .
Translational study protocols in cell-based therapy for neonatal hypoxic-ischemic injury Many variables contribute to designing translational studies, some of which include harvesting stem cells, delivery method, optimal dose, and timing of transplantation. To best approximate a clinical setting, the laboratory parameters for testing should resemble clinical expectations to provide the best conditions for a translational approach. Conditions for harvesting stem cells include factors such as autologous versus allogenic, embryonic versus extraembryonic, pluripotency versus differentiated, and the potential for tumorigenesis. Another particular limitation is calculating a therapeutic cell dose while avoiding a potential microembolic event, seen at high-dose injections. Thus, thorough testing and consideration is required to balance the benefits versus consequences. Further, candidate stem cell therapeutic products must be delivered through a safe and efficacious delivery system. Minimally invasive delivery will prevent additional trauma to an already injured brain. As for timing of cell delivery, research suggests a neuroprotective phase of less than 1 day of injury and a neurorestorative phase of greater than 1 day after injury [14] .
In an attempt to enhance the successful outcome of cell therapy in stroke patients, academicians, industry partners, and regulators, including the National Institutes of Health (NIH) and the US Food and Drug Administration (FDA), have collaborated to form Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS) [11, [15] [16] [17] [18] [19] . Further, Baby STEPS strives to apply the same goals to cell therapy for neonatal hypoxic-ischemic brain injury [20] .
Safety and efficacy of cell therapy
When embarking on the search for novel therapeutics, safety and efficacy is no exception. Cell-based therapy is of no exception. Some methods of assessing the safety and efficacy of experimental treatments for HIE include behavioral tests and histological assessment. Behavioral tests serve to evaluate motor and cognitive improvements in experimental groups, whereas histological assays assess decreased cell loss/apoptosis, reduction of inflammation, neurogenesis, and suppressed oxidative stress, all of which may indicate modes of action and brain remodeling [21] . Further histological evaluation is necessary to analyze the characteristics, as discussed above, of the grafted cells within the hypoxic-ischemic tissue, as well as tumorigenesis or ectopic tissue formation [22] .
The described assessments should be carried out for both short-and long-term to examine the immediate and prolonged effects [23] . Such evaluations are complicated in neonatal HIE because of endogenous spontaneous recovery during both developmental and maturation periods in the neonatal animal [24] and pediatric patients [25] .
Two clinical trials are underway in the USA (Duke University and Medical College of Georgia) to evaluate the safety and efficacy of umbilical cord blood transplants in CP patients. The transplantation of autologous cord blood in children with CP has been established as safe; however, long-term follow-up is necessary to ensure that there are no future complications [12, 26] .
Although cell-based therapy serves as a strong therapeutic foundation in the treatment of neonatal hypoxic-ischemic brain injury, there is much room for improvement. One such aspect for therapeutic exploration is the possibility of therapy combining the metabolic benefits of hypothermia, detailed in the following sections, with the potential neuroprotective and neurorestorative benefits of the stem cell-based approach mentioned above.
Hypothermia as a treatment for neonatal hypoxic-ischemic injury
In animal models of HIE, hypothermia decreases glutamate release, attenuates secondary energy failure [7, 27, 28] , normalizes protein synthesis, and reduces injury secondary to free-radical production [29] . Hypothermia has further demonstrated neuroprotective effects against HIE events subsequent to aberrant stages of region-specific brain maturation [30] , blood-brain barrier dysfunction, and mitochondrial impairment-induced apoptosis [31] . The exact mechanism of action underlying the effects of hypothermia is still unclear, but may include reduction in oxidative stress, energy deficits, and inflammation [32] .
Hypothermic treatment characteristics
As discussed above, the observation of early seizure activity may indicate HIE, and possibly severe brain injury in newborns, prompting the notion of a critical relationship between onset of the symptoms and the start of therapy. Thus, any treatment modality, including hypothermia, is likely to exert its maximal benefit if induced rapidly, ideally within 6 h after the hypoxicischemic injury, and continued over the following 12 h or further [33] .
Safety and efficacy of hypothermia
To date, small trials have yielded promising results in evaluating the safety of hypothermia in neonates [27] . Some of these randomized trials further demonstrated neurodevelopmental improvement in mild-to-moderate HIE. However, no significant improvement was seen in severe conditions of HIE in the neonatal population [7, 8, 34] . More recently, studies on the reduction of neurodevelopmental disability have suggested a neuroprotective effect of hypothermia at 18 months of age in patients with moderate or severe HIE [35] .
Hypothermic neuroprotective approaches may lead to a reduction in the risk of developing neurodevelopmental disabilities, but areas of the brain already subjected to damage may still require a cell-based therapy, suggesting a tandem combination approach of both hypothermia and cell transplantation.
Combination therapy of cell transplantation and hypothermia
Currently, therapeutic options for HIE in human neonates seek to interrupt the cascade of events leading to injury, including magnesium, calcium channel blockers, and NMDA receptor antagonists. These routes have yet to yield significant results in preventing neuronal loss [29, 36] . As discussed above, considering the established research on hypothermic and cell-based therapeutic options individually, combination therapy may yield greater functional recovery. As additional interventions emerge, such as use of erythropoietin and helium [37, 38] , we may find that a composite mixture of treatment modalities could further enhance clinical efficacy as compared with stand-alone therapy.
Bone marrow-derived stem cells, such as mesenchymal stem cells (MSCs), have demonstrated mobilization, experimentally, into the periphery in response to physiological stress. Once in the periphery, these cells are recruited to areas of injury, as is the case in HIE [39] . Clinically, a benefit of MSCs is their potential ease for harvesting. Because they are present in umbilical cord blood, adipose tissue, amniotic fluid/tissue, and menstrual blood [40] , there are multiple sources available for obtaining these cells. Further, because of their immature immune status, allogenic transplants (harvested from nonself) may prove to be as safe as autologous transplants in terms of graft rejection. Prior research has demonstrated therapeutic effects of MSC transplantation in brain injury [41] , although further research is essential to establish its efficacy in the treatment of HIE and in combination therapy.
Delta opioid agonists may result in states resembling physiological states of hibernation, such as hypothermia [42] , through direct opioid receptor and non-opiod mechanisms [43] . Substantiating a functional role of opioids, delta opioids may regulate neural stem and progenitor cell proliferation and differentiation [44] , and possibly enhance cell-based therapeutics [45] . We recently demonstrated that the effect of moderate hypothermic treatment in an in vitro model of hypoxic-ischemic injury Advancing critical care medicine for cerebral palsy Dailey et al. 1069 was enhanced by MSC treatment [46] . The combination therapy of moderate hypothermia and MSCs proved to be the optimal condition for preserving cell survival and mitochondrial activity under oxygen-glucose deprivation conditions. Follow-up investigations of signaling pathways demonstrated growth factor upregulation and anti-apoptotoic function complementing the observed benefits.
Despite all the treatment options surfacing, the best predictor for favorable outcomes will likely be early detection of at-risk newborns. The ability to intervene before pervasive damage by hypoxic-ischemic events may best facilitate the prevention of lifelong disabilities [47] .
A first case report
Although stem cell-based therapy for neonatal hypoxicischemic brain injury is largely experimental, limited trials involving autologous use of umbilical cord blood cells for treatment of children with CP are underway. A recently published case report describes the use of human cord blood for neuroregeneration in a child with CP who had suffered a cardiac arrest. At two and a half years of age, the child suffered from global ischemic brain damage, secondary to cardiac arrest, resulting in a vegetative state. After autologous intravenous transplantation with cord blood and rehabilitation, the child demonstrated exceptional motor recovery and a reduction in other symptoms at his 2-month follow-up [48] . Researchers attribute this functional neuroregeneration not only to rehabilitation therapy but also to more likely being mediated by stem cell transplantation, suggesting that the time for clinical use of cell-based therapies for CP has arrived.
Conclusion
Despite the promising results indicated by the case report above, extensive preclinical safety and efficacy research is still needed to extend these therapies to other neonatal diseases. This research begins with establishing standardized experimental models and carrying out quantitative assessments to predict clinical therapeutic capacity. The goal for the emergent future will be optimizing the aforementioned conditions. The optimal dose, delivery, and timing are under still under investigation. Current anecdotal reports of clinical improvement following cell therapy in children with CP or HIE should not compromise the Baby STEPS' footing on the need for solid preclinical studies to support the clinical trials. The discussion above on the Baby STEPS' guidelines may be applicable to other experimental therapies for neonatal hypoxic-ischemic injury [49] and should be used in concert with existing pediatric stroke recommendations for research and treatment interventions [50] .
Experimental research on translational cell-based therapy for adult stroke continues to emerge. Although many of these principles may be applicable to the neonatal population, the differences in pathophysiology warrant distinct trials to advance cellular therapy in this arena. Above, we have outlined the specific benefits of both stem cell therapy and hypothermia as innovative research modalities with direct clinical applications in the treatment of CP. As with many current clinical treatment protocols, the use of a sole stand-alone therapy is rare, necessitating the need for combination therapy. However, research on combination therapy remains an underexplored theme. Thus, future research is essential for determining any beneficial or harmful outcome of combination therapy. Moving forward, these outcomes must be assessed for both behavioral and histological parameters. There is urgent demand to introduce novel therapies for CP in children. Given the critical and debilitating nature of the disease, we must remain proactive in advancing therapy from the bench to the bedside.
